- Home
- MVSTW vs RVMDW Comparison
MVSTW vs RVMDW Comparison
Compare MVSTW & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVSTW
- RVMDW
- Stock Information
- Founded
- MVSTW 2006
- RVMDW 2014
- Country
- MVSTW United States
- RVMDW United States
- Employees
- MVSTW N/A
- RVMDW 534
- Industry
- MVSTW Industrial Machinery/Components
- RVMDW
- Sector
- MVSTW Miscellaneous
- RVMDW
- Exchange
- MVSTW Nasdaq
- RVMDW Nasdaq
- Market Cap
- MVSTW N/A
- RVMDW N/A
- IPO Year
- MVSTW N/A
- RVMDW N/A
- Fundamental
- Price
- MVSTW $0.20
- RVMDW $0.11
- Analyst Decision
- MVSTW
- RVMDW
- Analyst Count
- MVSTW 0
- RVMDW 0
- Target Price
- MVSTW N/A
- RVMDW N/A
- AVG Volume (30 Days)
- MVSTW 126.0K
- RVMDW 15.6K
- Earning Date
- MVSTW 03-14-2025
- RVMDW 02-26-2025
- Dividend Yield
- MVSTW N/A
- RVMDW N/A
- EPS Growth
- MVSTW N/A
- RVMDW N/A
- EPS
- MVSTW N/A
- RVMDW N/A
- Revenue
- MVSTW $370,989,000.00
- RVMDW $742,000.00
- Revenue This Year
- MVSTW N/A
- RVMDW N/A
- Revenue Next Year
- MVSTW N/A
- RVMDW N/A
- P/E Ratio
- MVSTW N/A
- RVMDW N/A
- Revenue Growth
- MVSTW 39.03
- RVMDW N/A
- 52 Week Low
- MVSTW $0.35
- RVMDW $0.10
- 52 Week High
- MVSTW $0.44
- RVMDW $0.12
- Technical
- Relative Strength Index (RSI)
- MVSTW N/A
- RVMDW N/A
- Support Level
- MVSTW N/A
- RVMDW N/A
- Resistance Level
- MVSTW N/A
- RVMDW N/A
- Average True Range (ATR)
- MVSTW 0.00
- RVMDW 0.00
- MACD
- MVSTW 0.00
- RVMDW 0.00
- Stochastic Oscillator
- MVSTW 0.00
- RVMDW 0.00
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About RVMDW Revolution Medicines Inc. Warrant
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.